Ernst & Young

EQS-News: Wirecard: EY tries to wriggle out of legal liability - how aggrieved Wirecard investors go on the counterattack

Retrieved on: 
Wednesday, April 10, 2024
Section 22, Partnership, Wirecard, URL, EY, News, Ernst & Young, Security (finance)

Aggrieved Wirecard investors are preparing to counterattack.

Key Points: 
  • Aggrieved Wirecard investors are preparing to counterattack.
  • Allegedly, EY Germany only wants to adapt its legal structures to what is customary in other countries.
  • Schirp & Partner Rechtsanwälte in Berlin/Germany, who are representing the largest group of aggrieved Wirecard shareholders who brought legal action before the Munich courts against EY, assess the situation differently.
  • We are convinced that EY is primarily concerned with limiting liability for the Wirecard scandal and getting the three fleeing "service lines", i.e.

Hazelcast Announces Stephen Weston as Chief Scientist

Retrieved on: 
Thursday, April 4, 2024
Volvo, Organization, Target, Risk management, Learning, Ernst & Young, Science, Internet of things, Financial services, Research, Global 2000, Imperial College London, Fintech, JPMorgan Chase, Machine learning, Medical device

Palo Alto, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Hazelcast, Inc. , the company that enables instant action on all data, announces Dr. Stephen Weston as its chief scientist, bringing deep ML and AI expertise to Hazelcast’s leadership in AI application and data infrastructure.

Key Points: 
  • Palo Alto, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Hazelcast, Inc. , the company that enables instant action on all data, announces Dr. Stephen Weston as its chief scientist, bringing deep ML and AI expertise to Hazelcast’s leadership in AI application and data infrastructure.
  • Weston, a Ph.D. in mathematical finance, brings 30 years of experience to the role in areas such as AI, risk management, and mathematical modeling.
  • In addition to his position as chief scientist at Hazelcast, Weston supervises academic research in the department of computing at Imperial College London, where the research group develops models that integrate technology, science and finance.
  • He and Weston are leading a deep bench of fintech and AI experts at Hazelcast.

Gabelli Convertible and Income Securities Fund Appoints Christina A. Peeney to Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Middlesex College (New Jersey), Fordham University, Ernst & Young, Retirement, Business, Rutgers University, Fund

RYE, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of The Gabelli Convertible and Income Securities Fund Inc. (NYSE: GCV ) (the “Fund”) announced the appointment of Christina A. Peeney to the Board of the Fund effective February 13, 2024.

Key Points: 
  • RYE, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of The Gabelli Convertible and Income Securities Fund Inc. (NYSE: GCV ) (the “Fund”) announced the appointment of Christina A. Peeney to the Board of the Fund effective February 13, 2024.
  • Ms. Peeney is an Adjunct Professor in the Business and Computer Science Department at Middlesex County College in Edison, New Jersey.
  • She was previously an auditor at Ernst & Young LLP and a Senior Account Executive at Prudential Investments Retirement Services.
  • in English Literature from Rutgers University and an M.B.A. in Finance from the Gabelli School of Business at Fordham University.

Endeavour Announces Completion of Investigation and Key Findings

Retrieved on: 
Wednesday, March 27, 2024
Remuneration, Linklaters, Documentation, Ernst & Young, Finance, Risk, Sale, LLP, Interview, Record, Nature, Allied Gold, Investigation, MAR, Bank statement, TSX, OTCQX, M&A, Audit committee, Person, Cryptocurrency

Mr de Montessus provided implausible and untrue explanations of his conduct during the course of the Investigation.

Key Points: 
  • Mr de Montessus provided implausible and untrue explanations of his conduct during the course of the Investigation.
  • Srinivasan Venkatakrishnan (“Venkat”), Chairman of Endeavour, commented: “The Board’s actions illustrate the high importance we place on integrity, governance and transparency.
  • Prior to the conclusion of the investigation work, Mr de Montessus was interviewed for a second time in late February.
  • Despite extensive efforts, the Investigation was not able to establish the ultimate beneficiaries of the payments to this third-party entity.

Mega Uranium Announces Results of Annual Shareholder Meeting

Retrieved on: 
Tuesday, March 26, 2024
University, Uranium, Thunderbird Entertainment, Ernst & Young, Entrepreneurship, General counsel, Tulane University Law School, Knowledge, Chairperson, Toronto International Film Festival, Cerebral palsy, Mining, CPA

At the meeting, shareholders also appointed Ernst & Young LLP as the company’s auditors, to hold office until the next annual meeting.

Key Points: 
  • At the meeting, shareholders also appointed Ernst & Young LLP as the company’s auditors, to hold office until the next annual meeting.
  • Complete voting results of the meeting are available under the company’s profile on sedar.com.
  • She currently serves on the boards and audit committees (including as Chair) of junior mining companies engaged in uranium and gold exploration.
  • Since 2014, she has dedicated her time to a grass roots charity she created which provides financial assistance to families with children with cerebral palsy.

Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update

Retrieved on: 
Tuesday, March 26, 2024
LLP, Ernst & Young

CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) --  Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced today that Ernst & Young LLP, the Company’s independent registered public accounting firm for the fiscal year ended May 28, 2023, determined that it declined to stand for reappointment as the Company’s independent registered public accounting firm for the Company’s fiscal year ending May 26, 2024 following the filing of the Company’s Annual Report on Form 10-K. Lifecore’s board of directors has initiated a search for a replacement.

Key Points: 
  • CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) --  Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced today that Ernst & Young LLP, the Company’s independent registered public accounting firm for the fiscal year ended May 28, 2023, determined that it declined to stand for reappointment as the Company’s independent registered public accounting firm for the Company’s fiscal year ending May 26, 2024 following the filing of the Company’s Annual Report on Form 10-K. Lifecore’s board of directors has initiated a search for a replacement.
  • In addition, the Company expects to provide a business update on Monday, April 1, 2024, which is expected to include certain select financial data for fiscal year 2024 and an update on commercial business matters.

GDS Appoints Jamie Khoo As CEO of GDS International

Retrieved on: 
Tuesday, March 26, 2024
Accounting, SVP, GDS, Operational excellence, Ernst & Young, ABB, Series, ST Telemedia

SHANGHAI, China, March 26, 2024 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS”, “GDSH” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced the appointment of Ms. Jamie Khoo, currently the Chief Operating Officer (“COO”) of GDS, as the Chief Executive Officer (“CEO”) of DigitalLand Holdings Limited (“GDS International” or “GDSI”), the holding company for GDS’s international data center assets and operations.

Key Points: 
  • SHANGHAI, China, March 26, 2024 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS”, “GDSH” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced the appointment of Ms. Jamie Khoo, currently the Chief Operating Officer (“COO”) of GDS, as the Chief Executive Officer (“CEO”) of DigitalLand Holdings Limited (“GDS International” or “GDSI”), the holding company for GDS’s international data center assets and operations.
  • The appointment is effective at the closing of the Series A capital raise of GDS International which has been announced today.
  • “We are delighted to announce Jamie’s appointment as the CEO of GDS International,” commented Mr. William Huang, Chairman and CEO of GDS.
  • With her leadership, I am confident that GDS International will continue its successful development in international markets.

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Hepatitis, KPMG, GNI, Cirrhosis, Patient, Chronic obstructive pulmonary disease, Sale, Coagulopathy, Ernst & Young, Idiopathic pulmonary fibrosis, Fibrosis, Therapy, COPD, Marketing, Partnership, Arthur Andersen, Audit committee, SAN, Safety, CVR, CHB, Fatty liver disease, Prevalence, Pharmacy, Hospital, Research, Acquisition, TGF, Pirfenidone, GAAP, Toxicity, Inflammation, Accounting, Entecavir, Loss, Orthostatic hypertension, IPF, Partner, NASH, Category 1, Pharmaceutical industry

Mr. Nussbaum brings nearly four decades of experience in accounting and financial reporting in the U.S. and Asia Pacific Region.

Key Points: 
  • Mr. Nussbaum brings nearly four decades of experience in accounting and financial reporting in the U.S. and Asia Pacific Region.
  • In October 2023, Gyre (formerly known as Catalyst Biosciences, Inc. (“Catalyst”)) completed the previously announced business combination with GNI Group Ltd. (“GNI”) and related entities.
  • In October 2023, Gyre Pharmaceuticals completed enrollment of its Phase 3 trial in patients with CHB-associated liver fibrosis in the PRC.
  • Use of Non-GAAP Financial Measures by Gyre Therapeutics, Inc.
    Gyre reports financial results in accordance with accounting principles generally accepted in the United States (“GAAP”).

Brighthouse Financial Appoints Michael J. Inserra and Lizabeth H. Zlatkus to Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Other Professional Services, Insurance, Finance, Asset Management, Personal Finance, Brighthouse Financial, Indivior, Inserra Supermarkets, Risk management, Ernst & Young, The Hartford, EY, Audit committee, Lisabeth, Moore Capital Management, Retirement, Management

Brighthouse Financial, Inc. (“Brighthouse Financial” or the “Company”) (Nasdaq: BHF) announced that today its Board of Directors (the “Board”) appointed Michael J.

Key Points: 
  • Brighthouse Financial, Inc. (“Brighthouse Financial” or the “Company”) (Nasdaq: BHF) announced that today its Board of Directors (the “Board”) appointed Michael J.
  • (“Mike”) Inserra and Lizabeth H. Zlatkus as independent members of the Board.
  • Mr. Inserra and Ms. Zlatkus were also each designated by the Board as an “audit committee financial expert” under applicable U.S. Securities and Exchange Commission rules and appointed to serve on the Audit Committee.
  • “Mike and Lizabeth each bring valuable experience in the insurance and financial services industries, along with strong leadership skills, financial expertise and deep knowledge of operations and risk management,” said C. Edward (“Chuck”) Chaplin, chairman of the Board, Brighthouse Financial.

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Retrieved on: 
Thursday, March 21, 2024
Certified Public Accountant, Questrom School of Business, KPMG, Business administration, Accounting, SAN, Ernst & Young, Therapy, Partner, Partnership, Arthur Andersen, Audit committee, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company’s Board of Directors and as a member of its Audit Committee.

Key Points: 
  • SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company’s Board of Directors and as a member of its Audit Committee.
  • “He joins our Board at a pivotal time as we advance our diversified pipeline of anti-fibrotic therapies.
  • We look forward to leveraging his expertise to help drive Gyre’s commercial growth.”
    “I am thrilled to have the opportunity to join the Gyre Board of Directors at such an exciting time for the Company,” said Mr. Nussbaum.
  • Mr. Nussbaum is a retired Certified Public Accountant and currently serves as an independent board member for Cullgen and Zeal Senior Living.